A Professional Service Provider for the Pharma Industry
Companies can stop studies before reaching projected enrollment numbers. It could be a decision based on a planned interim analysis (IA) or it could be for ‘administrative’ reasons. The latter may not indicate that a company has fallen on hard times financially; it could be the result of operational problems Continue reading THE UTILITY OF FUTILITY
Sulopenem / ORLYNVAH approved for uUTI When Iterum, a Pfizer spin-off of sorts, took over sulopenem development in 2015, there was still hope for approvals of this drug in multiple indications such as uUTI, cUTI, cIAI and even CABP. Ten years later and after an FDA rejection CRL in 2021, Continue reading Sulopenem uUTI – Does It Suffice?
With the average number of 6-7 authors per (clinical) publication and an increasing trend for multi-authored articles there are now plenty of opportunities for industrious clinicians to publish. Here are just a few examples of super-achievers from the Infectious Disease space: By simple math, we can see that these gentlemen Continue reading PUBLICATION OVERACHIEVERS